Intravitreal and Intracameral DEX in NPDR

Condition(s) studied

Investigational drug(s) / intervention(s)

Dexamethasone sodium phosphate: In patients with stable DR and no significant macular edema, intravitreal anti-VEGF injections after phacoemulsification surgery can prevent the worsening of postoperative macular edema and potentially improve final visual outcomes while maintaining safety. Laser coagulation and intravitreal anti-VEGF injections are currently considered the standard treatments for PDR. However, the cost of anti-VEGF drugs often prevents many patients from receiving regular and timely injections. Intravitreal corticosteroids may be used as an alternative to anti-VEGF agents.

Study summary

To investigate the effects of intravitreal and intracameral injection of dexamethasone during cataract phacoemulsification in patients with mild to moderate non-proliferative diabetic retinopathy

Eligibility

Primary outcome measure(s)

• measure the central point thickness (CPT) and central foveal thickness (CFT) — From enrollment to the end of treatment at 3 months
  optical coherence tomography (OCT) was used to perform the retinal examination, macular cube scans (512 × 128) and measure the central point thickness (CPT) and central foveal thickness (CFT). The CPT measurement focused on a central circle with a diameter of 1mm, and the CFT was calculated as the average of three consecutive measurements

Trial sites (1)

More Affiliated Hospital of Nantong University trials in China

Other trials for the same condition